Appeal on fixed-dose combo drugs?

| Updated on January 16, 2018 Published on December 09, 2016


Healthcare advocacy groups and the pharma industry will be watching for developments this fortnight on the fixed-dose combination medicines (FDCs) controversy. Earlier this month, the Delhi High Court had quashed the Government's ban on 344 FDCs. An FDC combines two or more medicines in one pill or product. And they came under the scanner as the rationale behind the combination was called into question. While some drugs may have a legitimate scientific rationale or may have brought a genuine convenience to the patient, many are a product of mere commercial reasons, say health advocacy representatives.Will the Centre appeal the High Court judgement in the same court, or approach the Supreme Court?

Published on December 09, 2016
This article is closed for comments.
Please Email the Editor